ONYX THERAPEUTICS, INC.
Patent Owner
Stats
- 46 US PATENTS IN FORCE
- 3 US APPLICATIONS PENDING
- Jan 30, 2018 most recent publication
Details
- 46 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 1,722 Total Citation Count
- Apr 14, 2005 Earliest Filing
- 16 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
| Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
Publication #
Title
Filing Date
Pub Date
Intl Class
2016/0177,402 IMMUNOGLOBULIN EXPRESSION LEVELS AS BIOMARKER FOR PROTEASOME INHIBITOR RESPONSEAug 08, 14Jun 23, 16[A61K, C12Q, G01N]
2015/0209,282 LIPOSOMAL COMPOSITIONS OF EPOXYKETONE-BASED PROTEASOME INHIBITORSJul 17, 13Jul 30, 15[A61K]
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
9403868 Crystalline tripeptide epoxy ketone protease inhibitorsMar 05, 15Aug 02, 16[A61K, C07D, C07K]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2015/0209,281 LIPOSOMAL COMPOSITIONS OF EPOXYKETONE-BASED PROTEASOME INHIBITORSAbandonedJul 17, 13Jul 30, 15[A61K]
2014/0105,921 Prodrugs of Peptide Epoxy Ketone Protease InhibitorsAbandonedJul 09, 13Apr 17, 14[A61K, C07K]
2013/0303,465 Cylodextrin Complexation Methods for Formulating Peptide Proteasome InhibitorsAbandonedSep 13, 12Nov 14, 13[A61K, A61P]
2013/0303,482 Cylodextrin Complexation Methods for Formulating Peptide Proteasome InhibitorsAbandonedSep 13, 12Nov 14, 13[A61K, A61P]
2012/0329,705 COMPOUNDS FOR PROTEASOME ENZYME INHIBITIONAbandonedJun 08, 12Dec 27, 12[A61K, A61P, C07K]
2011/0236,428 COMBINATION THERAPY WITH PEPTIDE EPOXYKETONESAbandonedOct 21, 09Sep 29, 11[A61K, A61P]
2010/0240,903 CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORSAbandonedMar 22, 10Sep 23, 10[C07D]
Top Inventors for This Owner
| Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.
